Current Rheumatology Reports

, Volume 6, Issue 1, pp 66–69

US and UK guidelines for glucocorticoid-induced osteoporosis: Similarities and differences

  • Juliet Compston
Article

Abstract

Osteoporosis is a common and serious complication of glucocorticoid therapy. Recent advances in the epidemiology, pathophysiology, and management of glucocorticoid-induced osteoporosis have stimulated the development of guidelines for the prevention and treatment of this condition. In this report, the updated recommendations of the American College of Rheumatology and guidelines recently produced by the Bone and Tooth Society, National Osteoporosis Society, and Royal College of Physicians in the UK are discussed with respect to their similarities and differences.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Walsh LJ, Wong CA, Pringle M, Tattersfield AE: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996, 313:344–346.PubMedGoogle Scholar
  2. 2.
    van Staa TP, Leufkens HGM, Abenhaim L, et al.: Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105–111.PubMedCrossRefGoogle Scholar
  3. 3.
    van Staa TP, Leufkens HGM, Abenhaim L, et al.: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993–1000. This paper utilizes information from the UK General Practice Research Database to document fracture risk at different doses of oral glucocorticoids. It demonstrates that the risk of fracture is increased even at doses lower than 7.5 mg oral prednisolone daily and that the increase in risk occurs during the first 3 to 6 months after starting glucocorticoids.PubMedCrossRefGoogle Scholar
  4. 4.
    van Staa TP, Leufkens HGM, Cooper C: Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 16:581–588.PubMedCrossRefGoogle Scholar
  5. 5.
    van Staa TP, Leufkens HGM, Cooper C: A meta-analysis of the epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int 2002, 13:777–787.PubMedCrossRefGoogle Scholar
  6. 6.
    Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382–387.PubMedCrossRefGoogle Scholar
  7. 7.
    Saag KG, Emkey R, Schnitzer TJ, et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292–299.PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999, 42:2309–2318.PubMedCrossRefGoogle Scholar
  9. 9.
    Reid DM, Hughes RA, Laan RFJM, et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000, 15:1006–1013.PubMedCrossRefGoogle Scholar
  10. 10.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496–1503.CrossRefGoogle Scholar
  11. 11.
    American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations for the prevention and reatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996, 39:1791–1801.CrossRefGoogle Scholar
  12. 12.
    Guidelines Working Group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians: Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London, UK: Royal College of Physicians; 2002.Google Scholar
  13. 13.
    Adami S, Fossaluzza V, Rossini N, et al.: The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 1991, 15:72–81.CrossRefGoogle Scholar
  14. 14.
    Khan SA, Kanis JA, Vasikaran S, et al.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700–1707.PubMedCrossRefGoogle Scholar
  15. 15.
    Sambrook P: Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000, 15:7645–7649.Google Scholar
  16. 16.
    Kanis JA, Johnell O, Oden A, et al.: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989–995. This paper highlights the strong effect of age as a risk factor for osteoporotic fracture, independent of bone mineral density, and emphasizes the importance of considering age when making decisions about intervention to prevent fracture.PubMedCrossRefGoogle Scholar
  17. 17.
    Johnell O, de Laet C, Johansson H, et al.: Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 2002, 13(suppl):S14. This study provides evidence that glucocorticoids increase bone fragility independent of their effects on bone mineral density and provide a rationale for intervention at higher bone density levels than in postmenopausal osteoporosis.CrossRefGoogle Scholar
  18. 18.
    Luengo M, Picado C, Delrio L, et al.: Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991, 46:803–806.PubMedCrossRefGoogle Scholar
  19. 19.
    Stellon AJ, Davies A, Webb A, Williams R: Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J 1985, 61:791–796.PubMedGoogle Scholar
  20. 20.
    Välimäki MJ, Kinnunen K, Tähtelä R, et al.: A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int 1999, 10:128–136.PubMedCrossRefGoogle Scholar
  21. 21.
    Lambrinoudaki A, Chan DTM, Lau CS, et al.: Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy: a randomized, double-blind, placebo controlled study. J Rheumatol 2000, 27:1759–1765.PubMedGoogle Scholar
  22. 22.
    Buckley LM, Leib ES, Cartularo KS, et al.: Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996, 125:961–968.PubMedGoogle Scholar
  23. 23.
    Adachi JD, Cranny A, Goldsmith CH, et al.: Intermittent cyclic therapy with etidronate in the prevention of corticosteroidinduced bone loss. J Rheumatol 1994, 21:1922–1926.PubMedGoogle Scholar
  24. 24.
    Bernstein CN, Seeger M, Anton PA, et al.: A randomized placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Thera 1996, 10:777–786.CrossRefGoogle Scholar
  25. 25.
    Bijlsma JWJ, Raymakers JA, Mosch C, et al.: Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 1988, 6:113–119.PubMedGoogle Scholar
  26. 26.
    Amin S, LaValley MP, Simms RW, Felson DT: The role of vitamin D in corticosteroid-induced osteoporosis. Arthritis Rheum 1999, 42:1740–1751.PubMedCrossRefGoogle Scholar
  27. 27.
    Homik J, Suarez-Almazor ME, Shea B, et al.: Calcium and vitamin D for corticosteroid-induced osteoporosis. In The Cochrane Library. Oxford: Update Software; 2000.Google Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Juliet Compston
    • 1
  1. 1.Department of MedicineUniversity of Cambridge School of Clinical Medicine, Addenbrooke’s HospitalCambridgeUK

Personalised recommendations